Anodic oxidation of 5-aminouracil
Anodizing 5-aminouracil with an aqueous base and subsequent hydrolysis produces 3,6-diaminopyrazine-2,5-dicarboxylic acid, addressing the toxicity issues of existing methods and enhancing the production of high-value intermediates for medical contrast agents.
Patent Information
- Application Number
- JP2022521457
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-10-10
- Filing Date
- 2020-10-09
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2040-10-09
AI Technical Summary
Existing methods for producing 4,9-dihydroxypyrimido[4,5-g]pteridine-2,7-bis(olate) and 3,6-diaminopyrazine-2,5-dicarboxylic acid utilize toxic and environmentally harmful substances, posing environmental and hygiene risks.
Anodizing 5-aminouracil in the presence of an aqueous base to form pyrimid[4,5-g]pteridine-2,4,7,9-tetraol, followed by basic hydrolysis to produce 3,6-diaminopyrazine-2,5-dicarboxylic acid, using environmentally friendly reagents and processes.
The method reduces environmental impact and improves industrial hygiene by providing a safer and more efficient production process for high-value intermediates used in products like medical contrast agents.
Smart Images

Figure 0007579849000031 
Figure 0007579849000032 
Figure 0007579849000033
Abstract
Description
[Technical field]
[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims priority to U.S. Provisional Patent Application No. 62 / 913,196, filed October 10, 2019, the entire disclosure of which is incorporated herein by reference.
[0002] (Technical field) The field of the disclosure relates generally to anodization chemistry.
[0003] More specifically, the disclosure relates to the anodic oxidation of 5-aminouracil to produce potassium 4,9-dihydroxypyrimido[4,5-g]pteridine-2,7-bis(olate), which is then hydrolyzed to produce 3,6-diaminopyrazine-2,5-dicarboxylic acid, an intermediate used in the manufacture of high value products such as imaging agents. [Background technology]
[0004] Methods for the preparation of 4,9-dihydroxypyrimido[4,5-g]pteridine-2,7-bis(olate) and 3,6-diaminopyrazine-2,5-dicarboxylic acid are known in the art. Problematically, the prior art methods use toxic and environmentally harmful substances (environmentally burdensome substances).
[0005] Therefore, there is a need for a new method for producing potassium 4,9-dihydroxypyrimido[4,5-g]pteridine-2,7-bis(olate) and 3,6-diaminopyrazine-2,5-dicarboxylic acid that reduces the environmental load and alleviates industrial hygiene problems. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] U.S. Pat. No. 5,294,711 [Patent Document 2] US Patent No. 2018 / 0010881 Summary of the Invention [Means for solving the problem]
[0007] In some embodiments of the present disclosure, a method for producing a divalent salt of pyrimido[4,5-g]pteridine-2,4,7,9-tetraol (compound 2) is provided. The method of the present disclosure includes step 1a of anodizing 5-aminopyrimidine-2,4(1H,3H)-dione (compound 1) in the presence of an aqueous base to produce pyrimido[4,5-g]pteridine-2,4,7,9-tetraol (compound 2a), and then step 1b of treating compound 2a with a base to produce compound 2, which is a divalent salt of pyrimido[4,5-g]pteridine-2,4,7,9-tetraol, as shown in the following formula.
[0008] [ka]
[0009] In the above formula, A + is a monovalent cation.
[0010] In some embodiments of the present disclosure, a method for preparing a substituted pteridine compound or a salt thereof is provided. The method of the present disclosure includes step 1a, in which compound 7 is anodized in the presence of a base and a solvent to produce compound 8, as shown in the following formula:
[0011] [ka]
[0012] In the above formula, R i and R ii are independent of each other, Hydrogen (in that case, R i and R ii is hydrogen), optionally substituted alkyl; optionally substituted esters; optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; optionally substituted aryl or optionally substituted heteroaryl; optionally substituted alkoxy; optionally substituted -C(O)-alkyl; optionally substituted amino; an optionally substituted polyol ether or an optionally substituted polyether; Polypeptide chain (AA); and Polysaccharide chains (PS). [Brief description of the drawings]
[0013] [Figure 1] Figure 1 illustrates a method for producing 3,6-diaminopyrazine-2,5-dicarboxylic acid according to the present disclosure. Figure 1 further illustrates a method for producing (2R,2'R)-2,2'-((3,6-diaminopyrazine-2,5-dicarbonyl)bis(azanediyl))bis(3-hydroxypropanoic acid) from 3,6-diaminopyrazine-2,5-dicarboxylic acid according to the present disclosure. [Diagram 2] Fig. 2 shows a first conventional method for producing 3,6-diaminopyrazine-2,5-dicarboxylic acid. Fig. 2 also shows a first conventional method for producing (2R,2'R)-2,2'-((3,6-diaminopyrazine-2,5-dicarbonyl)bis(azanediyl))bis(3-hydroxypropanoic acid) from 3,6-diaminopyrazine-2,5-dicarboxylic acid. [Diagram 3] FIG. 3 shows a second prior art synthesis of 3,6-diaminopyrazine-2,5-dicarboxylic acid. [Figure 4] FIG. 4 illustrates a method for making substituted pyrazine-2,5-dicarboxylic acids in accordance with the present disclosure. [Diagram 5] FIG. 5 illustrates a method for making substituted pyrazine-2,5-dicarboxylic acids in accordance with the present disclosure. [Figure 6]FIG. 6 illustrates a method for making substituted pyrazine-2,5-dicarboxylic acids in accordance with the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] The present disclosure generally relates to an improved method for preparing a salt of pyrimido[4,5-g]pteridine-2,4,7,9-tetraol (compound 2) by anodic oxidation of 5-aminouracil (5-aminopyrimidine-2,4(1H,3H)-dione) (compound 1). In some embodiments, compound 2 is converted by basic hydrolysis to 3,6-diaminopyrazine-2,5-dicarboxylic acid (compound 3), which is useful as an intermediate in the manufacture of high-value products. In some such embodiments, compound 3 is used as an intermediate in the manufacture of medical imaging agents. One such imaging agent is 3,6-diaminopyrazine-2,5-dicarboxylic acid, which is useful, for example, but not limited to, as a fluorescent dye for use in assessing renal function and imaging vasculature (e.g., the ocular vasculature). A method for preparing compound 3 according to the present disclosure is shown in FIG. 1 as steps 1 and 2. One particular aspect of the present disclosure relates to a method for producing (2R,2′R)-2,2′-((3,6-diaminopyrazine-2,5-dicarbonyl)bis(azanediyl))bis(3-hydroxypropanoic acid) (compound 6) from compound 3, which is shown as Steps 3 and 4 in FIG. 1.
[0015] A first prior art method for the preparation of 3,6-diaminopyrazine-2,5-dicarboxylic acid is shown as steps 1 and 2 in FIG. 2. In step 1 of FIG. 2, 3,6-diamino-2,5-pyrazinedicarbonitrile (compound 7) is contacted with sulfuric acid to produce 3,6-diaminopyrazine-2,5-dicarboxamide (compound 8). The problem is that this prior art method starts with compound 7, which is typically prepared by a complicated and environmentally harmful method as taught in U.S. Pat. No. 5,294,711. U.S. Pat. No. 5,294,711 teaches reacting diphenyl disulfide with hydrogen cyanide in an organic solvent (e.g., dimethoxyethane, acetonitrile, xylene, chloroform, methanol, or benzene) to produce 2,3-diamino-3-(phenylthio)acrylonitrile ("DAAN"), which is then converted to compound 7 by contacting DAAN with citric acid. In step 2 of Figure 2, compound 8 is contacted with KOH to produce 3,6-diaminopyrazine-2,5-dicarboxylic acid (compound 3). Figure 2 further illustrates a prior art method (step 3) in which compound 3 is contacted with benzyl D-serinate hydrochloride (compound 4) in the presence of hydroxybenzotriazole (racemization inhibitor: "HOBt"), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (carboxyl activator: "EDC"), and N,N-diisopropylethylamine ("i-PrNEt", base) in dimethylformamide ("DMF") solvent to produce dibenzyl 2,2'-((3,6-diaminopyrazine-2,5-dicarbonyl)bis(azanediyl))(2R,2'R)-bis(3-hydroxypropionate) (compound 5). FIG. 2 further illustrates a prior art method for preparing compound 6 by contacting compound 5 with a palladium catalyst in an ethanol / water solvent (Step 4).
[0016] A second prior art method for producing 3,6-diaminopyrazine-2,5-dicarboxylic acid is shown in FIG. 3 as steps 1 and 2. In step 1 of FIG. 3, compound 1 is contacted with potassium ferrocyanide (KFe(CN)) in aqueous KOH to produce potassium 4,9-dihydroxypyrimido[4,5-g]pteridine-2,7-bis(olate) (compound 9). In step 2 of FIG. 3, compound 9 is converted to compound 3 by basic hydrolysis. The problem is that potassium ferrocyanide is classified as an environmental hazard due to its irritant properties to the human body, its release of toxic hydrogen cyanide when it comes into contact with acid, and its toxicity to aquatic organisms. The prior art method of FIG. 3 is taught, for example, by Oskar Baudisch, et al., The Oxidation of 5- Aminouracil, J. Biol. Chem., 71:497-499 (1927); E. C. Taylor, et al., Pyrimidopteridines by Oxidative Self-condensation of Aminopyrindines, J. Am. Chem. Soc., 77, (8), 2243-2247 (1955); and D. Kaminsky, et al., Some Congeners and Analogs of Dipyridamole, J. Med. Chem., 9, 610 (1966).
[0017] The present applicant has discovered an anodization process for producing pyrimido[4,5-g]pteridine-2,4,7,9-tetraol (compound 2a) and its salts that is environmentally friendly and can avoid the use of hazardous reactants. The reaction process is shown in FIG. 1 as steps 1a and 1b, and generally involves anodizing compound 1 in the presence of an aqueous base to produce compound 2a, which is then treated with a base to produce compound 2, as shown in the following formula:
[0018] [ka]
[0019] Here, A + is H + Or a monovalent cation. The yield of compound 2 based on compound 1 is at least 20%, at least 30%, or at least 40%, for example, 20%, 25%, 30%, 35%, or 40%.
[0020] Without intending to be bound by any particular theory, one theory is that the reaction mechanism for step 1 is as shown in the following equation, which shows KOH as the base:
[0021] [ka]
[0022] A + Cations (e.g., K + The number of ) relates to the stoichiometry of the base to the free acid. The salt form can be mono-, di-, tri-, or tetra-.
[0023] Bases within the scope of the present disclosure include cations and anions, and also include inorganic and organic bases. Inorganic bases include sodium, potassium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum salts. Non-limiting examples include phosphates such as dipotassium monohydrogen phosphate, potassium dihydrogen phosphate, tripotassium phosphate, disodium monohydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, diammonium monohydrogen phosphate, ammonium dihydrogen phosphate, and triammonium phosphate; acetates such as potassium acetate, sodium acetate, and ammonium acetate; formates such as potassium formate and sodium formate; carbonates such as potassium carbonate, sodium carbonate, potassium bicarbonate, and sodium bicarbonate; and alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, rubidium hydroxide, cesium hydroxide, magnesium hydroxide, calcium hydroxide, manganese (II) hydroxide, iron hydroxide, cobalt hydroxide, nickel (II) hydroxide, copper (II) hydroxide, zinc hydroxide, and cadmium hydroxide. The organic base has the general formula: R-amine (e.g., R + OH - ) and OR - where R is an organic moiety such as alkyl, aryl, etc. Examples of organic bases include primary amines, secondary amines, tertiary amines, substituted amines including naturally occurring substituted amines, and cyclic amines such as pyridine, isopropylamine, trimethylamine, diethylamine, triethylamine, triethanolamine, diisopropylamine, ethanolamine, 2-diethylaminoethanol, trimethylamine, dicyclohexylamine, ethylenediamine, purine, piperazine, piperidine, N-ethylpiperidine, and alkali metal alkoxides (e.g., sodium methoxide). In some embodiments, the base is a strong base such as an alkali metal hydroxide base. Non-limiting examples of suitable bases include sodium hydroxide and potassium hydroxide.
[0024] In some embodiments, the solvent is a polar solvent. In some embodiments, the solvent is a polar protic solvent. Non-limiting examples of suitable polar protic solvents include water, methanol, ethanol, n-propanol, i-propanol, n-butanol, acetic acid, and any combination thereof. In some embodiments, the solvent is water. In some embodiments, the solvent is a polar solvent. In some embodiments, the solvent is a polar protic solvent. Non-limiting examples of suitable polar protic solvents include water, methanol, ethanol, n-propanol, i-propanol, n-butanol, acetic acid, and any combination thereof. In some embodiments, the solvent is water. In some embodiments, compound 2 is the potassium salt of compound 2a, as shown below.
[0025] [ka]
[0026] 4,9-Dihydroxypyrimido[4,5-g]pteridine-2,7-bis(olate)potassium.
[0027] Electrochemical cells known in the art are generally suitable for implementing the present disclosure and may include divided or non-divided cells. For example, but not limited to, the electrochemical cell may be a divided flow cell. A divided flow cell generally includes two parallel rectangular electrode plates separated by a membrane located approximately equidistant from each electrode. The electrode package is generally housed in a chemically stable non-conductor (e.g., polypropylene) configured to house both the electrodes and the separation membrane, thereby allowing separate and approximately uniform solvent flow over both electrodes. The solvent flow may form a recirculation pump system in which the anolyte and catholyte are circulated through the respective compartments. Optionally, a heat exchanger may be incorporated to maintain the reaction temperature within a certain set range.
[0028] In other configurations, an undivided cell may be used in which the membrane or porous barrier is removed, allowing the electrolyte to pass freely between the electrodes.
[0029] In some embodiments, an indirect electrochemical system can be used. For example, but not limited to, iron(II) complexes can be anodically converted to iron(III) with high current efficiency and extent (>90%). Compound 2 or a salt thereof can be produced by reacting an anolyte solution containing Fe(III) with compound 1.
[0030] In another embodiment, an electrochemical catalytic system can be used. For example, but not limited to, a complex of Fe(II) can be anodic converted to Fe(III) in the presence of compound 2 to produce compound 2 or a salt thereof, regenerating Fe(II) available for reoxidation at the anode to produce more Fe(III). Thus, this reaction is catalytic for Fe(II).
[0031] In some embodiments, compound 2 can be hydrolyzed in aqueous base to produce compound 3, as shown in step 2 of FIG. 1. The reaction scheme is as follows: + is H + Or a monovalent cation.
[0032] [ka]
[0033] In some such embodiments, compound 2 is potassium 4,9-dihydroxypyrimido[4,5-g]pteridine-2,7-bis(olate). In some embodiments, the base is a strong base, such as NaOH or KOH. The hydrolysis step produces compound 3 in aqueous solution as a salt of a basic cation. In some further embodiments, after the hydrolysis step, an acid is added to the aqueous solution to precipitate compound 3 (a diacid) in the aqueous solution to form a slurry. In some embodiments, the acid is a strong acid, such as, for example, but not limited to, HCl. Solid compound 3 can be isolated from the slurry by methods known in the art, such as filtration or centrifugation. The isolated compound 3 is optionally further purified by washing and optionally dried.
[0034] In some embodiments, compound 3 can be reacted with NHR, an acid salt (compound 4) in a solvent to generate the corresponding amide (compound 5), as shown in step 3 of Figure 1. The reaction scheme is as follows:
[0035] [ka]
[0036] The general method of producing an amide by coupling a compound having an amine substituent (e.g., compound 4) with a compound having a carboxyl substituent (e.g., compound 3) is known to those skilled in the art. In particular, US 2018 / 0010881 (which is incorporated herein by reference in its entirety) discloses compound 3, 6-diamino-N 2 , N 5 The present invention discloses a compound for producing 3,6-diamino-N-bis(D-serine)-pyrazine-2,5-dicarboxamide as follows: 2 , N 5-Bis(O-benzyl-(D)-serine methyl ester)-pyrazine-2,5-dicarboxamide was prepared as follows: A mixture of sodium 3,6-diaminopyrazine-2,5-dicarboxylate (300 mg, 1.24 mmol), (D)-Ser(OBn)-OMe-HCl salt (647 mg, 2.64 mmol), HOBt-H2O (570 mg, 3.72 mmol), and EDC-HCl (690 mg, 3.60 mmol) in DMF (25 mL) was treated with TEA (2 mL). The resulting mixture was stirred for 16 h and concentrated. The mixture was concentrated to dryness and the residue was partitioned with EtOAc and water. The layers were separated and the EtOAc solution was washed with saturated NaHCO3 and brine. The solution was dried over anhydrous Na2SO4, filtered, and concentrated to give 370 mg (51% yield) of the bisamide as a light yellow powder: 1 NMR (300MHz, CDCl3) δ8.47(d, J=8.74Hz, 2H), 7.25~7.37(complex m, 10H), 5.98(bs, 4H), 4.85(dt, J=8.7, 3.3Hz, 2H), 4.56( ABq, J=12.6, Hz, Av=11.9Hz, 4H), 3.99 (1 / 2 of ABq in d, J=8.7, 3.3, Av unclear, 2H), 3.76~3.80 (1 / 2 of ABq unclear, 2H), 3.78 (s, 6H). 13 C NMR (75 MHz, CDCl3) δ 170.5 (s), 165.1 (s), 146.8 (s), 138.7 (s) 128.6 (d), 128.1 (d), 127.8 (d), 126.9 (s), 73.5 (t), 69.8 (t), 53.0 (q), 52.9 (q). LCMS (5-95% gradient acetonitrile in 0.1% TFA over 10 min), single peak retention time = 4.93 min on a 30 mm column, (M+H). + = 581. In step 2, 3,6-diamino-N 2 , N 5-Bis(O-benzyl-(D)-serine)-pyrazine-2,5-dicarboxamide was prepared as follows: The product from step 1 (370 mg, 0.64 mmol) in THF (10 mL) was treated with 1.0 N sodium hydroxide (2.5 mL). After stirring at room temperature for 30 min, the reaction was judged complete by TLC. 1.0 N HCl was added to adjust the pH to approximately 2, and the resulting solution was extracted (3×) with EtOAc. The layers were combined, dried over sodium sulfate, filtered, and concentrated to give 353 mg (100% yield) of the diacid as an orange foam: LCMS (5-95% gradient acetonitrile in 0.1% TFA over 10 min), retention time = 4.41 min on a 30 mm column, (M+H) + = 553. In step 3, 3,6-diamino-N 2 , N 5 -Bis(D-serine)-pyrazine-2,5-dicarboxamide was prepared as follows: To the product from step 2 (353 mg, 0.64 mmol) in methanol (20 mL) was added 5% Pd / C (300 mg) and ammonium formate (600 mg). The resulting reaction was heated at reflux for 2 h. The reaction was cooled to room temperature, filtered through a plug of celite, and concentrated. The residue was recrystallized from methanol-ether to give 191 mg (80% yield) of the title compound of Example 2 as a yellow foam: 1 NMR (300 MHz, DMSO-d6) δ 8.48 (d, J = 6.9 Hz, 2H), 6.72 (bs, 4H), 3.95 (apparent quartet, J = 5.1 Hz, 2H), 3.60 (apparent ABq of doublet); downfield group centered at 3.71, J = 9.9, 5.1 Hz, 2H; upfield group centered at 3.48, J = 209.9, 6.3 Hz, 2H. 13 C NMR (75 MHz, CDCl3) δ 172.9 (s), 164.9 (s), 147.0 (s), 127.0 (s), 62.9 (d), 55.7 (t). LCMS (gradient between 5-95% acetonitrile in 0.1% TFA over 10 min), single peak retention time = 1.45 min on a 30 mm column, (M+H). + = 373. UV / vis (100 μM in PBS) λ abs= 434 nm. Fluorescence λ ex = 449 nm, λ em =559nm.
[0037] One of ordinary skill in the art will appreciate that 3,6-diaminopyrazine-2,5-dicarboxylate can be reacted with amines other than (D)-Ser(OBn)-OMe-HCl salt to produce amides of the structure of compound 6. For example, US Pat. No. 5,999,366 further provides examples of the production of amides in which the (D)-Ser(OBn)-OMe-HCl salt amine is replaced with (L)-Ser(OBn)-OMe-HCl, bis-2-(methoxyethyl)amine, racemic (2,2-dimethyl-1,3-dioxolan-4-yl)methanamine, tert-butyl 2-aminoethylcarbamate, Asp(OBn)-OMe-p-TosH salt, 2-OBn-β-serine-OMe-HCl salt, m-dPEG24-amine, 3-aminopropionic acid p-toluenesulfonate benzyl, 4-amino-butyrate HCl ethyl salt, 3-amino-5-oxo-furan HCl salt, 3-dimethyl-β-alanine ethyl ester HCl salt, ethyl 3-(3-pyridyl)-propionic acid HCl salt, or methyl-2-O-benzyl-3-amino-propionic acid HCl salt.
[0038] In some embodiments, the solvent is a polar solvent. In some embodiments, the solvent is a polar aprotic solvent. Non-limiting examples of suitable solvents include tetrahydrofuran, DMF, ethyl acetate, acetonitrile, and any combination thereof. In some embodiments, the solvent is DMF.
[0039] The reaction mixture of step 3 may further include a racemization inhibitor, such as, but not limited to, HOBt, 7-aza-1-hydroxybenzotriazole, ethyl 2-cyano-2-(hydroxyimino)acetate, N-hydroxysuccinimide, or hydroxy-3,4-dihydro-4-oxo-1,2,3 benzotriazine. The reaction mixture of step 3 may further include a coupling agent (e.g., a carboxyl group activator), such as, but not limited to, EDC or N,N'-dicyclohexylcarbodiimide. The reaction mixture of step 3 may further include a base, such as, but not limited to, an organic amine base, such as i-PrNEt or N-methylmorpholine.
[0040] In some embodiments, the NHR, acid salt, is a polypeptide chain comprising one or more natural or non-natural α-amino acids linked together by peptide bonds. The polypeptide chain (AA) can be a homopolypeptide chain or a heteropolypeptide chain and can be of any suitable length. For example, in some embodiments, the polypeptide chains are 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 109, 102, 104, 105, 106, 107, 108, 109, 109, 109, 1 The polypeptide chain (AA) may be 1, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 α-amino acids, 1-90 α-amino acids, 1-80 α-amino acids, 1-70 α-amino acids, 1-60 α-amino acids, 1-50 α-amino acids, 1-40 α-amino acids, 1-30 α-amino acids, 1-20 α-amino acids, or 1-10 α-amino acids. In some embodiments, the α-amino acids of the polypeptide chain (AA) are selected from aspartic acid, asparagine, arginine, histidine, lysine, glutamic acid, glutamine, serine, and homoserine. In some aspects, the α-amino acids of the polypeptide chain (AA) are selected from aspartic acid, glutamic acid, serine, and homoserine. In some aspects, the polypeptide chain (AA) refers to a single amino acid (e.g., aspartic acid or serine). In some aspects, the amino acid is D-serine.
[0041] In some embodiments, the NHR acid salt is NHR 1 R 2 It is.
[0042] In such an embodiment, each R 1 are independent of each other, -(CH2)<h2 style=";text-align:left;direction:ltr"> a <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> b <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> c <h2 style=";text-align:left;direction:ltr"> NR<h2 style=";text-align:left;direction:ltr"> 10 <h2 style=";text-align:left;direction:ltr"> CONR<h2 style=";text-align:left;direction:ltr"> 11 <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> d <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> e <h2 style=";text-align:left;direction:ltr"> R<h2 style=";text-align:left;direction:ltr"> 20 <h2 style=";text-align:left;direction:ltr"> 、<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> -(CH2)<h2 style=";text-align:left;direction:ltr"> a <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> b <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> c <h2 style=";text-align:left;direction:ltr"> NR<h2 style=";text-align:left;direction:ltr"> 12 <h2 style=";text-align:left;direction:ltr"> CSNR<h2 style=";text-align:left;direction:ltr"> 13 <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> d <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> e <h2 style=";text-align:left;direction:ltr"> R<h2 style=";text-align:left;direction:ltr"> 21 <h2 style=";text-align:left;direction:ltr"> 、<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> -(CH2)<h2 style=";text-align:left;direction:ltr"> a <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> b <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> c <h2 style=";text-align:left;direction:ltr"> CONR<h2 style=";text-align:left;direction:ltr"> 14 <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> d <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> e <h2 style=";text-align:left;direction:ltr"> R<h2 style=";text-align:left;direction:ltr"> 22 <h2 style=";text-align:left;direction:ltr"> 、<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> -(CH2)<h2 style=";text-align:left;direction:ltr"> a <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> b <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> c <h2 style=";text-align:left;direction:ltr"> NR<h2 style=";text-align:left;direction:ltr"> 15 <h2 style=";text-align:left;direction:ltr"> SO2(CH2)<h2 style=";text-align:left;direction:ltr"> d <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> e <h2 style=";text-align:left;direction:ltr"> R<h2 style=";text-align:left;direction:ltr"> 23 <h2 style=";text-align:left;direction:ltr"> 、<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> -(CH2)<h2 style=";text-align:left;direction:ltr"> a <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> b <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> c <h2 style=";text-align:left;direction:ltr"> SO2NR<h2 style=";text-align:left;direction:ltr"> 16 <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> d <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> e <h2 style=";text-align:left;direction:ltr"> R<h2 style=";text-align:left;direction:ltr"> 24 <h2 style=";text-align:left;direction:ltr"> 、<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> -(CH2)<h2 style=";text-align:left;direction:ltr"> a <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> b <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> c <h2 style=";text-align:left;direction:ltr"> NR<h2 style=";text-align:left;direction:ltr"> 17 <h2 style=";text-align:left;direction:ltr"> CO(CH2)<h2 style=";text-align:left;direction:ltr"> d <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> e <h2 style=";text-align:left;direction:ltr"> R<h2 style=";text-align:left;direction:ltr"> 25 <h2 style=";text-align:left;direction:ltr"> 、<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> -(CH2)<h2 style=";text-align:left;direction:ltr"> a <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> b <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> c <h2 style=";text-align:left;direction:ltr"> NR<h2 style=";text-align:left;direction:ltr"> 18 <h2 style=";text-align:left;direction:ltr"> CO2(CH2)<h2 style=";text-align:left;direction:ltr"> d <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)e R 26 、 -(CH2) a (CH2CH2O) b (CH2) c OC(O)NR 19 CO2(CH2) d (CH2CH2O) e R 27 、 -(CH2) c OR 68 、-CH2(CHOH) c R 69 、-CH2(CHOH) c CO2H,-(CHCO2H) c CO2H,-(CH2) c NR 70 R 71 、-CH[(CH2) f NH2] c CH2H、-CH[(CH2) f NH2] c CH2OH、-CH2(CHNH2) c CH2NR 72 R 73 、-(CH2CH2O) e R 74 ,-(CH2) t CO(CH2CH2O) e R 75 、 -(CH2) u (CH2CH2O) j (CH2) k NR 58 C(O)NR 59 (CH2) l (CH2CH2O) o R 76 、 -(CH2) u (CH2CH2O) j (CH2) k NR 60 C(S)NR 61 (CH2) l (CH2CH2O) o R 77 、 -(CH2) u (CH2CH2O) j (CH2) k<h2 style=";text-align:left;direction:ltr">C(O)NR<h2 style=";text-align:left;direction:ltr"> 62 <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> l <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> o <h2 style=";text-align:left;direction:ltr"> R<h2 style=";text-align:left;direction:ltr"> 78 <h2 style=";text-align:left;direction:ltr"> 、<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> -(CH2)<h2 style=";text-align:left;direction:ltr"> u <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> j <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> k <h2 style=";text-align:left;direction:ltr"> S(O)2NR<h2 style=";text-align:left;direction:ltr"> 63 <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> l <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> o <h2 style=";text-align:left;direction:ltr"> R<h2 style=";text-align:left;direction:ltr"> 79 <h2 style=";text-align:left;direction:ltr"> 、<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> -(CH2)<h2 style=";text-align:left;direction:ltr"> u <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> j <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> k <h2 style=";text-align:left;direction:ltr"> NR<h2 style=";text-align:left;direction:ltr"> 64 <h2 style=";text-align:left;direction:ltr"> S(O)2(CH2)<h2 style=";text-align:left;direction:ltr"> l <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> o <h2 style=";text-align:left;direction:ltr"> R<h2 style=";text-align:left;direction:ltr"> 80 <h2 style=";text-align:left;direction:ltr"> 、<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> -(CH2)<h2 style=";text-align:left;direction:ltr"> u <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> j <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> k <h2 style=";text-align:left;direction:ltr"> NR<h2 style=";text-align:left;direction:ltr"> 65 <h2 style=";text-align:left;direction:ltr"> C(O)(CH2)<h2 style=";text-align:left;direction:ltr"> l <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> o <h2 style=";text-align:left;direction:ltr"> R<h2 style=";text-align:left;direction:ltr"> 81 <h2 style=";text-align:left;direction:ltr"> 、<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> -(CH2)<h2 style=";text-align:left;direction:ltr"> u <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> j <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> k <h2 style=";text-align:left;direction:ltr"> NR<h2 style=";text-align:left;direction:ltr"> 66 <h2 style=";text-align:left;direction:ltr"> C(O)O(CH2)<h2 style=";text-align:left;direction:ltr"> l <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> o <h2 style=";text-align:left;direction:ltr"> R<h2 style=";text-align:left;direction:ltr"> 82 <h2 style=";text-align:left;direction:ltr"> 、<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> -(CH2)<h2 style=";text-align:left;direction:ltr"> u <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> j <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> k <h2 style=";text-align:left;direction:ltr"> OC(O)NR<h2 style=";text-align:left;direction:ltr"> 67 <h2 style=";text-align:left;direction:ltr"> (CH2)<h2 style=";text-align:left;direction:ltr"> l <h2 style=";text-align:left;direction:ltr"> (CH2CH2O)<h2 style=";text-align:left;direction:ltr"> o <h2 style=";text-align:left;direction:ltr"> R<h2 style=";text-align:left;direction:ltr"> 83 <h2 style=";text-align:left;direction:ltr"> 、<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> -(CH2)<h2 style=";text-align:left;direction:ltr"> a <h2 style=";text-align:left;direction:ltr"> SO3H、-(CH2)<h2 style=";text-align:left;direction:ltr"> a <h2 style=";text-align:left;direction:ltr"> SO3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 、-(CH2)<h2 style=";text-align:left;direction:ltr"> a <h2 style=";text-align:left;direction:ltr"> OSO3H、-(CH2)<h2 style=";text-align:left;direction:ltr"> a <h2 style=";text-align:left;direction:ltr"> SO3<h2 style=";text-align:left;direction:ltr"> - <h2 style=";text-align:left;direction:ltr"> 、-(CH2)<h2 style=";text-align:left;direction:ltr"> a <h2 style=";text-align:left;direction:ltr"> NHSO3H、-(CH2)<h2 style=";text-align:left;direction:ltr"> a <h2 style=";text-align:left;direction:ltr"> NHSO3- , -(CH2) a PO3H2, -(CH2) a PO3H - , -(CH2) a PO3 = , -(CH2) a OPO3H2, -(CH2) a OPO3H - , or -(CH2) a OPO 3 It is.
[0043] R 2 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 58 , R 59 , R 60 , R 61 , R 62 , R 63 , R 64 , R 65 , R 66 , and R 67 Each of, independently of the other, is -H or -CH3.
[0044] R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , and R 27 each of which, independently of the other, -H, -CH3, -(CH2) f NR 28 C(O)NR 29 (CH2) g (CH2CH2O) h R 38 , -(CH2) f NR 30 CSNR 31 (CH2) g(CH2CH2O) h R 39 , -(CH2) f C(O)NR 32 (CH2) g (CH2CH2O) h R 40 , -(CH2) f S(O)2NR 33 (CH2) g (CH2CH2O) h R 41 , -(CH2) f NR 34 S(O)2(CH2) g (CH2CH2O) h R 42 , -(CH2) f NR 35 C(O)(CH2) g (CH2CH2O) h R 43 , -(CH2) f NR 36 C(O)O(CH2) g (CH2CH2O) h R 44 , -(CH2) f OC(O)NR 37 (CH2) g (CH2CH2O) h R 45 , -CO(AA) or -CONH(PS).
[0045] R 28 , R 29 , R 30 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , R 42 , R 43 , R44 , R 45 , R 46 , R 47 , and R 48 Each of, independently of the other, is -H or -CH3.
[0046] R 68 , R 69 , R 70 , R 71 , R 72 , R 73 , R 74 , R 75 , R 76 , R 77 , R 78 , R 79 , and R 80 each of which, independently of the other, -H, -CH3, -(CH2) p S(O)2NR 84 (CH2) q (CH2CH2O) s R 81 , -(CH2) p NR 85 S(O)2(CH2) q (CH2CH2O) s R 83 , -(CH2) p NR 86 C(O)(CH2) q (CH2CH2O) s R 85 , -(CH2) p NR 86 C(O)O(CH2) q (CH2CH2O) s R 87 , -(CH2) p O.C.(O) q NR 88 (CH2) q (CH2CH2O) s R 87 ,or, -(CH2) p OC(O)NR 88 (CH2) q (CH2CH2O)s R 89 It is.
[0047] R 81 , R 82 , R 83 , R 84 , R 85 , R 86 , R 87 , R 88 , and R 89 Each of, independently of the other, is -H or -CH3.
[0048] AA is as defined above.
[0049] Each (PS) is, independently of the other, a sulfated or non-sulfated polysaccharide chain comprising one or more monosaccharide units linked together by glycosidic bonds. The polysaccharide chains (PS) can be of any suitable length. For example, in some embodiments, the polysaccharide chains can comprise 1-100 monosaccharide units, 1-90 monosaccharide units, 1-80 monosaccharide units, 1-70 monosaccharide units, 1-60 monosaccharide units, 1-50 monosaccharide units, 1-40 monosaccharide units, 1-30 monosaccharide units, 1-20 monosaccharide units, or 1-10 monosaccharide units. In some aspects, the polysaccharide chains (PS) are homopolysaccharide chains consisting of either pentose or hexose monosaccharide units. In other aspects, the polysaccharide chains (PS) are heteropolysaccharide chains consisting of one or both of pentose and hexose monosaccharide units. In some aspects, the monosaccharide units of the polysaccharide chain (PS) are selected from the group consisting of glucose, fructose, mannose, xylose, and ribose. In some aspects, the polysaccharide chain (PS) refers to a single monosaccharide unit (e.g., glucose or fructose).
[0050] t and u are, independently of each other, 1, 2, 3, 4, or 5.
[0051] Each of a, d, g, l, and q, independently of the others, is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0052] Each of c, f, k, and p, independently of the others, is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0053] Each of b, j, e, h, o, and s, independently of one another, is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100.
[0054] Each NHR moiety may optionally include a protecting group. In some such embodiments, the NHR is a polypeptide chain that includes one or more natural or non-natural α-amino acids linked together by peptide bonds that have protecting groups. In such embodiments, the protecting groups may suitably be, but are not limited to, benzyl ("Bn"), t-butyl, methyl, or p-methoxybenzyl.
[0055] In some embodiments, each NHR is a single protected amino acid. In some such embodiments, the amino acid is aspartic acid, asparagine, arginine, histidine, lysine, glutamic acid, glutamine, serine, or homoserine. In some such embodiments, the amino acid is aspartic acid or serine. In some embodiments, the amino acid is D-serine with a Bn protecting group.
[0056] In some embodiments, compound 5 is dibenzyl 2,2'-((3,6-diaminopyrazine-2,5-dicarbonyl)bis(azanediyl))(2R,2'R)-bis(3-hydroxypropionate), represented by the following structural formula:
[0057] [ka]
[0058] In the protecting group embodiment of the present disclosure, as shown in step 4 of FIG. 1, compound 6 can be generated by cleaving the protecting group from compound 5 as shown in the following scheme:
[0059] [ka]
[0060] In some embodiments, compound 6 is compound 6a, i.e., (2R,2′R)-2,2′-((3,6-diaminopyrazine-2,5-dicarbonyl)bis(azanediyl))bis(3-hydroxypropanoic acid), represented by the following structural formula:
[0061] [ka]
[0062] In some embodiments, the solvent is a non-polar solvent. In some embodiments, the solvent is a polar solvent. In some embodiments, the solvent is a polar protic solvent. Non-limiting examples of suitable polar protic solvents include water, methanol, ethanol, n-propanol, i-propanol, n-butanol, acetic acid, and any combination thereof. In some embodiments, the solvent is ethanol and water.
[0063] The deprotection reagent may be a catalyst, an acid, a base, or an oxidizing agent. The selection of a suitable deprotection reagent depends on the identity of the protecting group and the protecting compound. For example, some compounds or moieties, such as amino acids, peptides, and polypeptides, may be unstable to strong acids and strong bases. In such embodiments, a deprotection catalyst is suitable for carrying out the present disclosure. In such embodiments, suitable catalysts may include catalytically active metals such as palladium, platinum, cobalt, rhodium, nickel, ruthenium, osmium, iridium, and any combination thereof. In some embodiments, palladium on carbon (Pd-C) is a suitable deprotection catalyst. In some further embodiments, deprotection may be carried out over a catalyst in the presence of hydrogen.
[0064] In some embodiments, compound 5 and compound 6 may have a molecular weight of 20000 or less. In some such embodiments, the molecular weight is 15000, 14000, 13000, 12000, 11000, 10000, 9000, 8000, 7000, 6000, 5000, 4500, 4000, 3500, 3000, 2500, 2000, 1500, 1000, 900, 800, 700, 600, 500, 400, or 300 or less. In another embodiment, compound 5 and compound 6 may have a molecular weight of more than 20000. In some embodiments, the molecular weight is preferably about 300 to about 1000, or about 300 to about 750. In some embodiments, compound 6 has a molecular weight of about 300 to about 600, or about 300 to about 500.
[0065] The present disclosure provides an anodic process for producing substituted pteridine compound 8 or a salt thereof, and substituted pyrazine compound 9 or a salt thereof. The reaction scheme for compound 8 is as follows:
[0066] [ka]
[0067] Without being bound to a particular theory, the anodic oxidation of the substituted 5-aminouracil compound 7 to the substituted pteridine compound 8 proceeds according to the previously disclosed mechanism, where R i and R ii It is believed that the pyrimidine heteroatoms substituted with are not atoms present in the bridged ring of the resulting tricyclic pteridine. In any theory for the formation of substituted pteridine compound 8, the substitution of the nitrogen heteroatoms shown is believed to be suitable for the practice of the present disclosure since those nitrogen heteroatoms are not involved in the formation of the bridged ring in the anodic oxidation reaction. Compound 8 corresponds to the compound shown in the mechanism before keto-enol tautomerization, but one >NH moiety is replaced by R i Replaced by >NR i is generated, and the other >NH part is R ii Replaced by >NR ii is produced. The ">" refers to the bond of the hetero nitrogen atom.
[0068] The preparation of substituted 5-aminouracil compounds such as compound 7 is known to those skilled in the art. See, for example, Baraldi, PG, et al., Design, "Synthesis, and Biological Activity of Hybrid Compounds between Uramustine and DNA Minor Groove Binder Distamycin A", J. Med. Chem. 2002, 45, 3630-3638, the entire contents of which are incorporated herein. For example, in a heterocyclic substitution reaction, 5-nitropyrimidine-2,4(1H,3H)-dione is reacted with R i Leaving group and / or R ii The nitrogen heteroatom can be converted to R by reacting with a leaving group. i and / or R ii In some embodiments, the leaving group is a halogen anion, e.g., Br - The substitution reaction is shown below.
[0069] [ka]
[0070] Suitable solvents include polar aprotic solvents such as 2-methyltetrahydrofuran, tetrahydrofuran (THF), ethyl acetate, propyl acetate (e.g., isopropyl acetate, iPrOAc), acetone, dimethylsulfoxide, N,N-dimethylformamide (DMF), acetonitrile (CH3CN), N,N-dimethylacetamide, N-methylpyrrolidone (NMP), hexamethylphosphoramide, propylene carbonate, and the like. In some embodiments, the solvent is DMF. Suitable reducing agents are known in the art. In some embodiments, the reducing agent is NaH. Compound 7a can be produced by reducing the substituted 5-nitropyrimidine-2,4(1H,3H)-dione with hydrogen in the presence of a suitable catalyst, such as a Pd catalyst. Compound 7a can then be converted to a substituted pteridine, such as compound 8, as described elsewhere herein. In one particular embodiment shown in FIG. 4, 3,6-bis((2-(2-methoxyethoxy)ethyl)amino)pyrazine-2,5-dicarboxylic acid can be prepared from 5-nitropyrimidine-2,4(1H,3H)-dione and 1-bromo-2-(2-methoxyethoxy)ethane.
[0071] In some such embodiments, compound 10, or a salt thereof, can be produced by contacting compound 9 with a base, as shown in the following formula:
[0072] [ka]
[0073] The anodization reaction, base, and solvent conditions are as described elsewhere herein.
[0074] R i and R ii are each independently hydrogen (in which case, Ri and R ii where only one of R is hydrogen), optionally substituted alkyl; optionally substituted ester; optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; optionally substituted aryl or optionally substituted heteroaryl; optionally substituted alkoxy; optionally substituted -C(O)-alkyl; optionally substituted amino; optionally substituted polyol ether or optionally substituted polyether; a polypeptide chain (AA) as described elsewhere herein; and a polysaccharide chain (PS) as described elsewhere herein. In some embodiments, R i is H. In some embodiments, R i is H and R ii is an optionally substituted ester, such as ethyl acetate. In some embodiments, R i is H and R ii is an optionally substituted polyether, such as 2-(2-methoxyethoxy)ethane or polyethylene glycol ("PEG"), such as 12PEG.
[0075] As used herein, "alkyl" refers to the monovalent linear or branched saturated hydrocarbon moiety, consisting solely of carbon and hydrogen atoms, having 1 to 20, 1 to 10, 1 to 6, or 1 to 4 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl, n-hexyl, octyl, dodecyl, and the like. Alkyl groups can be optionally substituted as defined herein.
[0076] As used herein, "cycloalkyl" refers to a carbocyclic moiety consisting of a monocyclic or polycyclic ring. Cycloalkyl can be optionally substituted as defined herein. Examples of cycloalkyl moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like. Polycyclic ring structures include fused and bridged bicyclic, fused and bridged polycyclic, and spirocyclic hydrocarbon ring systems, such as bicyclo[2.2.1]heptane, pinane, bicyclo[2.2.2]octane, adamantane, and norborene. Cycloalkyl can be saturated or partially unsaturated (e.g., cycloalkenyl).
[0077] As used herein, the term "heterocycloalkyl" refers to a saturated or partially unsaturated ring system radical having the indicated number of ring atoms out of the total number recited and containing 1 to 5 heteroatoms selected from N, O, and S, where the nitrogen and sulfur atoms are optionally oxidized and the nitrogen atom is optionally quaternized as a ring atom (e.g., 3-12 membered heterocycloalkyl having 3 to 12 ring atoms and containing at least one heteroatom, such as C 2-11 Heterocycloalkyl may be optionally substituted as defined herein. A "heterocycloalkyl" ring system may be a monocyclic or a fused, bridged, or spirocyclic polycyclic (including fused bicyclic, bridged bicyclic, or spirocyclic) ring system.
[0078] As used herein, "aryl" refers to an alkyl group having 6 to 20 carbon atoms (C 20) monovalent aromatic hydrocarbon radical. Aryl includes bicyclic radicals consisting of an aromatic ring fused to a saturated, partially unsaturated, or aromatic carbocyclic ring. Common aryl groups include, but are not limited to, radicals derived from benzene (phenyl), substituted benzene, naphthalene, anthracene, biphenyl, indenyl, indanyl, 1,2-dihydronaphthalene, 1,2,3,4-tetrahydronaphthyl, and the like. Aryl groups are optionally substituted, independently of each other, with one or more substituents described herein. In some embodiments, aryl can be substituted with alkyl, cycloalkyl, halogen, or haloalkyl. The alkyl can be substituted directly on the heteronitrogen or can be linked to the heteronitrogen by an alkyl or substituted alkyl.
[0079] As used herein, the term "heteroaryl" refers to an aryl ring containing 1 to 5 heteroatoms selected from N, O, and S. The nitrogen and sulfur atoms are optionally oxidized and the nitrogen atom is optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom. Heteroaryl groups are optionally substituted, independently of each other, with one or more substituents described herein.
[0080] As used herein, "alkoxy" refers to a moiety of the structure: -OR, where R is an alkyl moiety as defined herein. Examples of alkoxy moieties include, but are not limited to, methoxy, ethoxy, isopropoxy, and the like.
[0081] As used herein, "haloalkyl" refers to an alkyl, as defined herein, in which one or more hydrogen atoms are replaced with the same or different halogen. Common haloalkyls include -CH2Cl, -CH2CF3, -CH2CCl3, -CF3, CHF2, and the like.
[0082] As used herein, "-C(O)-alkyl" refers to an optionally substituted aldehyde moiety that forms an amide with the heteronitrogen, i.e., >NC(O)-alkyl. Non-limiting examples of substituted NC(O)-alkyl include amide-ols, amide-diols, amide-polyols, and derivatives thereof.
[0083] As used herein, "polyol ether" and "polyether" are of the general structure where the heteronitrogen refers to the ring atom to which the polyol ether or polyether is attached.
[0084] [ka]
[0085] In the above formula, R a is optionally replaced by C 1-4 R is alkyl; b is optionally replaced by C 1-4 R is alkyl; c is optionally replaced by C 1-4 R is alkyl; d is optionally replaced by C 1-4 x is 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100, or any range constructed therein, such as, for example, 1-100, 1-70, 1-50, 1-30, 1-20, 2-20, 2-10, 3-20, 3-10, 5-20, or 5-10. a ~R c are C2 and R d is H or C 1-2 In one example, the polyether is PEG. In some non-limiting embodiments, the branched polyols and branched polyethers are of the general structure shown below: In the formula below, the hetero nitrogen refers to the ring atom to which the polyol ether or polyether is attached.
[0086] [ka]
[0087] In the above formula, R d is as defined herein, and y is 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50, or any range constructed therein, such as 1-50, 1-30, 1-20, 2-20, 2-10, 3-20, 3-10, 5-20, or 5-10. Non-limiting examples include the structures below: In the formula below, the hetero nitrogen refers to the ring atom to which the polyol ether or polyether is attached.
[0088] [ka]
[0089] As used herein, "halogen" refers to chlorine, fluorine, bromine, and iodine.
[0090] As used herein, "amino" refers to R x and R y where each of the structures is hydrogen -NR x R y "Monoalkylamino" refers to the R x and R x "Dialkylamino" refers to a structure in which one of R is hydrogen and the other is alkyl. x and R x is an alkyl group.
[0091] As used herein, "optionally substituted" refers to a moiety that may be unsubstituted or substituted with a specified group. Examples of substituents include, but are not limited to, hydroxy, alkyl, alkoxy, halo, haloalkyl, oxo, amino, monoalkylamino, or dialkylamino.
[0092] In some such embodiments, compound 10, or a salt thereof, can be reacted with an NHR acid salt (compound 4) in a solvent to produce compound 11, or a salt thereof, as shown in the following scheme:
[0093] [ka]
[0094] R and R ii and the reactions are as defined above in relation to the reaction of compound 3 with compound 4 to produce compound 5.
[0095] In an aspect of the present disclosure, each NHR The moiety contains a protecting group PG, which is cleaved to produce compound 13, or a salt thereof, as shown in the formula below and as described elsewhere herein in connection with compounds 5 and 6.
[0096] [ka]
[0097] Working Example
[0098] Example 1
[0099] 4,9-Dihydroxypyrimido[4,5-g]pteridine-2,7-bis(olate)potassium was prepared according to the following reaction scheme:
[0100] [ka]
[0101] In the first (anode) chamber, the inside walls of a Berzelius beaker (tall type, 400 mL) were lined with a platinum-coated titanium expanded mesh screen on which phytofelt anodes were evenly placed. A stainless steel cathode formed from 0.635 cm (0.25 inch) tubing was placed in a separate (cathode) chamber formed from PVC tubing, approximately 1.9 cm (3 / 4 inch) in outside diameter, approximately 15.24 cm (6 inches) in length, and sealed at one end with room temperature vulcanizing transparent silicone ("RTV"). The tube was perforated with 0.64 cm (1 / 4 inch) holes evenly spaced to a distance of approximately 10.2 cm (4 inches) from the bottom of the RTV plug. A woven Teflon reinforced (Rf[OCF2CF(CF3)2] n A Nafion N324 membrane, 0.15 mm (0.006 in) thick (OCF2CF2SO3H), was wrapped around a pvc support tube with its rough side facing the cathode and then sealed with silicone RTV, taking care not to contaminate the exposed side of the Nafion with the RTV. The Nafion membrane is configured to surround the tube, thereby preventing mixing between the two chambers while allowing charge transfer between the two chambers. The Nafion membrane was pretreated by immersing it in a KOH solution contained in a 100 mL graduated cylinder (the solution was mixed and stirred by hand). The membrane initially shrunk to about 1 / 2 its original diameter, but then expanded until it touched the walls of the graduated cylinder. The membrane was allowed to soak for at least 0.5 hours. It was then removed and rinsed with deionized water. The membrane was kept moist by storing it in a plastic bag. The cell was constructed with approximately 0.5 inch space at the bottom of the graphite felt anode in which a magnetic stir bar was placed. The cathode chamber tube was suspended in the center of the beaker (anode) assembly by attaching it to a three-pronged clamp.
[0102] The assembled two-chamber cell was filled with an aqueous KOH solution (4.2 g KOH in 160 mL deionized water) such that both chambers were filled to approximately equal levels. 5-Aminopyrimidine-2,4(1H,3H)-dione (5-aminouracil) (2.0 g, 0.0157 mole) was added to the anolyte and allowed to dissolve. A DC power supply (Lambda, Model LG-532) was connected and, with continuous stirring, 1.0 A (5.6 V) was passed through the cell until 2 Faradays of charge had passed (0.9 h). The anolyte turned red (from an initial yellow color) over the course of the reaction.
[0103] The anolyte and catholyte were each analyzed for the presence of the desired product by reversed-phase high performance liquid chromatography ("reHPLC"). The anolyte was confirmed to have significant amounts of potassium 4,9-dihydroxypyrimido[4,5-g]pteridine-2,7-bis(oleate). The catholyte was found to have no detectable amounts of potassium 4,9-dihydroxypyrimido[4,5-g]pteridine-2,7-bis(oleate).
[0104] Example 2
[0105] 3,6-Diaminopyrazine-2,5-dicarboxylic acid was prepared from potassium 4,9-dihydroxypyrimido[4,5-g]pteridine-2,7-bis(olate) according to the following reaction scheme.
[0106] [ka]
[0107] Two Teflon reaction vessels were each charged with 0.5 g of potassium 4,9-dihydroxypyrimido[4,5-g]pteridine-2,7-bis(olate) and a solution of 0.3-0.4 g of sodium hydroxide in 10 mL of deionized water. The vessels were secured to a microwave reactor and reacted at 170 °C and approximately 100 psig pressure for 1 h. The vessels were cooled to approximately 50 °C and the contents were filtered to remove a small amount of solid residue. The bright yellow filtrate was transferred to a 250 mL round bottom flask equipped with a large magnetic stir bar. The pH was adjusted to approximately 3 with concentrated HCl while stirring, forming a large amount of red precipitate. A few more drops of acid were added and the solid was collected by filtration on a glass frit, washed with cold 1 N HCl (1 × 10 mL), acetonitrile (2 × 30 mL), and diethyl ether (1 × 30 mL), sucked dry, and transferred to a vacuum oven. The collected solid was dried overnight at 45-50 °C to give 0.48 g of 3,6-diaminopyrazine-2,5-dicarboxylic acid (79%). 13 NMR (D2O / NaOD, external TMS standard) δ132.35, 147.32, 171.68.
[0108] Example 3
[0109] Each of the two cell compartments of an IKA ElectraSynPro-Divide 2-compartment cell equipped with a 5u porous polypropylene frit divider and stir bar was filled with 6.5 mL of 5-aminouracil potassium salt (0.10 g) in 13.0 mL of deionized water. The anode was reticulated carbon foam and the anode chamber was fitted with a thermocouple. The cathode was stainless steel.
[0110] The oxidation was carried out under constant current conditions (13 mA) for 100 min, at which point 62% of the 5-aminouracil had been consumed. The major product, 1,6-dihydropyrimido[4,5-g]pteridine-2,4,7,9(3H,8H)-tetrone, was quantified by HPLC and found to be produced in 22% yield (7 mg) based on the 5-aminouracil consumed.
[0111] Example 4
[0112] The conditions of Example 3 were repeated, except that the anode was replaced with a reticulated carbon foam anode of the same dimensions. The reaction proceeded with 32% conversion of 5-aminouracil and 11.2 mg of 1,6-dihydropyrimido[4,5-g]pteridine-2,4,7,9(3H,8H)-tetraone was found to be produced.
[0113] Example 5
[0114] The conditions of Example 4 were repeated, but the polarity of the electrodes was reversed every 10 seconds. The yield of 1,6-dihydropyrimido[4,5-g]pteridine-2,4,7,9(3H,8H)-tetraone was 26% based on the amount of 5-aminouracil consumed.
[0115] Example 6
[0116] The conditions of Example 3 were repeated, except that 27 mg of potassium ferrocyanide was added to the anolyte. The yield of 1,6-dihydropyrimido[4,5-g]pteridine-2,4,7,9(3H,8H)-tetraone was 39.2% based on the amount of 5-aminouracil consumed.
[0117] Example 7
[0118] The conditions of Example 3 were repeated, but with anodic potential control instead of the galvanostatic control used in Example 3. The anodic potential was held at 1.2 V vs. Ago / AgCl. After 140 min, the yield of 1,6-dihydropyrimido[4,5-g]pteridine-2,4,7,9(3H,8H)-tetraone was 41%, as determined by quantitative rpHPLC analysis based on the amount of 5-aminouracil consumed.
[0119] Example 8
[0120] The conditions of Example 3 were repeated, but the anode was replaced with glassy carbon, graphite, or platinum in separate experiments, and similar yields of 1,6-dihydropyrimido[4,5-g]pteridine-2,4,7,9(3H,8H)-tetraone as in Example 3 were obtained with each anode evaluated.
[0121] Example 9
[0122] The conditions of Example 3 were repeated, except that the porous polypropylene frit separator was removed in favor of a non-dividing cell. The yield of 1,6-dihydropyrimido[4,5-g]pteridine-2,4,7,9(3H,8H)-tetraone was 10% based on the amount of 5-aminouracil consumed.
[0123] Example 10 (Prophetic Example): Preparation of 1,6-bis(2-(2-methoxyethoxy)ethyl)-1,6-dihydropyrimido[4,5-g]pteridine-2,4,7,9(3H,8H)-tetrone (18).
[0124] As shown in FIG. 4, in step 1, 5-nitropyrimidine-2,4(1H,3H)-dione (14) is reacted with 1-bromo-2-(2-methoxyethoxy)ethane (15) to produce 1-(2-(2-methoxyethoxy)ethyl)-5-nitropyrimidine-2,4(1H,3H)-dione (16) according to the general procedure for the synthesis of compounds 4-9 outlined in the experimental section on page 3634 of Baraldi, PG, et al., J. Med. Chem., 2002, 45, 3630-3638.
[0125] As shown in FIG. 4, in step 2, compound 16 is reduced to 5-amino-1-(2-(2-methoxyethoxy)ethyl)pyrimidine-2,4(1H,3H)-dione (17) using 10% Pd on carbon in a suitable solvent such as 2-methoxyethanol essentially using the conditions of the general procedure for the synthesis of compounds 10-15 outlined on page 3635 of the reference cited in step 1.
[0126] As shown in FIG. 4, in step 3, electrochemical anodic oxidation of 5-amino-1-(2-(2-methoxyethoxy)ethyl)pyrimidine-2,4(1H,3H)-dione (17) is carried out using conditions substantially as described in Examples 1-9 to produce 1,6-bis-1,6-dihydropyrimidine[4,5-g]pteridine-2,4,7,9(3H,8H)-tetrone (18), which is isolated using reverse phase high pressure liquid chromatography, rpHPLC, or precipitation techniques known in the art.
[0127] Example 11 (Prophetic Example): Preparation of 3,6-bis((2-(2-methoxyethoxy)ethyl)amino)pyrazine-2,5-dicarboxylic acid (20)
[0128] As further shown in FIG. 4, using conditions substantially similar to those of Example 2, 1,6-bis(2-(2-methoxyethoxy)ethyl)-1,6-dihydropyrimido[4,5-g]pteridine-2,4,7,9(3H,8H)-tetrone (18) is converted to 3,6-bis((2-(2-methoxyethoxy)ethyl)amino)pyrazine-2,5-dicarboxylic acid (20).
[0129] Example 12 (Prophetic Example): Preparation of diethyl 2,2'-(2,4,7,9-tetraoxo-2,3,4,7,8,9-hexahydropyrimido[4,5-g]pteridine-1,6-diyl)diacetate (24).
[0130] As shown in FIG. 5, in step 1, 5-nitropyrimidine-2,4(1H,3H)-dione (14) is reacted with ethyl bromoacetate (21) to produce ethyl 2-(5-nitro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetate (22) according to the general procedure for the synthesis of compounds 4-9 outlined in the experimental section on page 3634 of Baraldi, PG, et al., J. Med. Chem., 2002, 45, 3630-3638.
[0131] As shown in FIG. 5, in step 2, compound 22 is reduced to ethyl 2-(5-amino-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetate (23) using 10% Pd on carbon in a suitable solvent such as 2-methoxyethanol essentially using the conditions of the general procedure for the synthesis of compounds 10-15 outlined on page 3635 of the reference cited in step 1.
[0132] As shown in FIG. 5, in step 3, electrochemical anodization of ethyl 2-(5-amino-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetate (23) is carried out using conditions substantially as described in Examples 1-9 to produce diethyl 2,2′-(2,4,7,9-tetraoxo-2,3,4,7,8,9-hexahydropyrimidine[4,5-g]pteridine-1,6-diyl)diacetate (24), which is isolated using reverse phase high pressure liquid chromatography, rpHPLC, or precipitation techniques known in the art.
[0133] Example 13 (Prophetic Example): Preparation of diethyl 2,2'-((3,6-dicarbamoylpyrazine-2,5-diyl)bis(azanediyl))diacetate (26)
[0134] As further shown in FIG. 5, using conditions substantially similar to those of Example 2, 2,2′-(2,4,7,9-tetraoxo-2,3,4,7,8,9-hexahydropyrimidine[4,5-g]pteridine-1,6-diyl)diacetate (24) is converted to diethyl 2,2′-((3,6-dicarbamoylpyrazine-2,5-diyl)bis(azanediyl))diacetate (26).
[0135] Example 14 (Prophetic Example): Preparation of 1,6-di(2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxaheptatriacontan-37-yl)-1,6-dihydropyrimido[4,5-g]pteridine-2,4,7,9(3H,8H)-tetraone (30).
[0136] As shown in FIG. 6, in step 1, 5-nitropyrimidine-2,4(1H,3H)-dione (14) is reacted with m-12PEG-bromide (27) to produce 1-(2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxaheptatriacontan-37-yl)-5-nitropyrimidine-2,4(1H,3H)-dione (28) according to the general procedure for the synthesis of compounds 4-9 outlined in the experimental section on page 3634 of Baraldi, PG, et al., J. Med. Chem., 2002, 45, 3630-3638.
[0137] As shown in FIG. 6, in step 2, compound 28 is reduced to 5-amino-1-(2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxaheptatriacontan-37-yl)pyrimidine-2,4(1H,3H)-dione (29) using 10% Pd on carbon in a suitable solvent such as 2-methoxyethanol essentially using the conditions of the general procedure for the synthesis of compounds 10-15 outlined on page 3635 of the reference cited in step 1.
[0138] As shown in FIG. 6, in step 3, electrochemical anodization of 5-amino-1-(2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxaheptatriacontan-37-yl)pyrimidine-2,4(1H,3H)-dione (29) is carried out using conditions substantially as described in Examples 1-9 to produce 1,6-di(2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxaheptatriacontan-37-yl)-1,6-dihydropyrimido[4,5-g]pteridine-2,4,7,9(3H,8H)-tetraone (30), which is isolated using reverse phase high pressure liquid chromatography, rpHPLC, or precipitation techniques known in the art.
[0139] Example 15 (Prophetic Example): Preparation of 3,6-bis((2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxaheptatriacontan-37-yl)-amino)pyrazine-2,5-dicarboxylic acid (32)
[0140] As further shown in FIG. 6, using conditions substantially similar to those of Example 2, 1,6-di(2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxaheptatriacontan-37-yl)-1,6-dihydropyrimido[4,5-g]pteridine-2,4,7,9(3H,8H)-tetraone (30) is converted to 3,6-bis((2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxaheptatriacontan-37-yl)-amino)pyrazine-2,5-dicarboxylic acid (32).
[0141] This specification uses examples to disclose the invention including the best mode and to enable any person skilled in the art to practice the invention, including making and using any device or system, and practicing any method incorporating the same. The patentable scope of the invention is defined by the claims, and may include alternative embodiments that occur to those skilled in the art. Such alternative embodiments are within the scope of the claims if they include elements that do not differ from the literal language of each claim, or if they include equivalent elements that do not differ substantially from the literal language of each claim.
Claims
1. 1. A method for preparing compound 2, which is a divalent salt of pyrimido[4,5-g]pteridine-2,4,7,9-tetraol, comprising the steps of: As shown in the formula below, Step 1a, anodizing 5-aminopyrimidine-2,4(1H,3H)-dione, compound 1, in the presence of aqueous base to produce pyrimido[4,5-g]pteridine-2,4,7,9-tetraol, compound 2a; and then step 1b, treating compound 2a with a base to produce compound 2, which is a divalent salt of pyrimido[4,5-g]pteridine-2,4,7,9-tetraol. 【Chemistry 1】 In the above formula, A + is a monovalent cation.
2. 2. The method of claim 1 , the base in step 1b is KOH; The compound 2 is 4,9-dihydroxypyrimido[4,5-g]pteridine-2,7-bis(olate)potassium, represented by the following structural formula: 【Chemistry 4】
3. 3. The method according to claim 1 or 2, The method, wherein steps 1a and 1b are carried out in an electrochemical cell.
4. 4. The method of claim 3, The method, wherein the electrochemical cell comprises a divided cell.
5. 4. The method of claim 3, The method, wherein the electrochemical cell comprises an undivided cell.
6. The method according to any one of claims 1 to 5, As shown in the formula below, The method further comprises hydrolyzing said compound 2 in the presence of a base to produce compound 3, which is 3,6-diaminopyrazine-2,5-dicarboxylic acid. 【Chemistry 20】
7. 7. The method of claim 6, As shown in the formula below, The method further comprises reacting said compound 3, which is 3,6-diaminopyrazine-2,5-dicarboxylic acid, with compound 4, which is an acid salt of NH2R, to produce compound 5: 【Chemistry 6】 In the above formula, Each NH2R is independently (i) a polypeptide chain comprising one or more natural or unnatural α-amino acids linked together by peptide bonds; or (ii) NH(R 1 ) and Each R 1 are independent of each other, -(CH 2 ) a (CH 2 CH 2 O) b (CH 2 ) c NR 10 P. 11 (CH 2 ) d (CH 2 CH 2 O) e R 20 、 -(CH 2 ) a (CH) 2 CH 2 O) b (CH) 2 ) c NR 12 CSNR 13 (CH) 2 ) d (CH) 2 CH 2 O) e R 21 、 -(CH 2 ) a (CH 2 CH 2 O) b (CH 2 ) c P. 14 (CH 2 ) d (CH 2 CH 2 O) e R 22 、 -(CH 2 ) a (CH 2 CH 2 O) b (CH 2 ) c NR 15 SO 2 (CH 2 ) d (CH 2 CH 2 O) e R 23 、 -(CH 2 ) a (CH 2 CH 2 O) b (CH 2 ) c SO 2 NR 16 (CH 2 ) d (CH 2 CH 2 O) e R 24 、 -(CH 2 ) a (CH 2 CH 2 O) b (CH 2 ) c NR 17 P. 2 ) d (CH 2 CH 2 O) e R 25 、 -(CH 2 ) a (CH 2 CH 2 O) b (CH 2 ) c NR 18 CO 2 (CH 2 ) d (CH 2 CH 2 O) e R 26 、 -(CH 2 ) a (CH 2 CH 2 O) b (CH 2 ) c P.S. 19 CO 2 (CH 2 ) d (CH 2 CH 2 O) e R 27 、 -(CH 2 ) c OR 68 、 -CH 2 (CHOH) c R 69 、 -CH 2 (CHOH) c CO 2 H、 -(EHCC) 2 H) c CO 2 H、 -(CH 2 ) c NR 70 R 71 、 -CH[(CH 2 ) f NH 2 ] c CO 2 H、 -CH[(CH 2 ) f NH 2 ] c CH 2 H -CH 2 (1) 2 ) c CH 2 NR 72 R 73 、 -(CH 2 CH 2 O) e R 74 、 -(CH 2 ) t CO(CH 2 CH 2 O) e R 75 、 -(CH 2 ) u (CH 2 CH 2 O) j (CH 2 ) k NR 58 C(O)NR 59 (CH 2 ) l (CH 2 CH 2 O) o R 76 、 -(CH 2 ) u (CH 2 CH 2 O) j (CH 2 ) k NR 60 C(S)NR 61 (CH 2 ) l (CH 2 CH 2 O) o R 77 、 -(CH 2 ) u (CH 2 CH 2 O) j (CH 2 ) k C(O)NR 62 (CH 2 ) l (CH 2 CH 2 O) o R 78 、 -(CH 2 ) u (CH 2 CH 2 O) j (CH 2 ) k S(O) 2 NR 63 (CH 2 ) l (CH 2 CH 2 O) o R 79 、 -(CH 2 ) u (CH 2 CH 2 O) j (CH 2 ) k NR 64 S(O) 2 (CH 2 ) l (CH 2 CH 2 O) o R 80 、 -(CH 2 ) u (CH 2 CH 2 O) j (CH 2 ) k NR 65 C(O)(CH 2 ) l (CH 2 CH 2 O) o R 81 、 -(CH 2 ) u (CH 2 CH 2 O) j (CH 2 ) k NR 66 C(O)O(CH 2 ) l (CH 2 CH 2 O) o R 82 、 -(CH 2 ) u (CH 2 CH 2 O) j (CH 2 ) k OC(O)NR 67 (CH 2 ) l (CH 2 CH 2 O) o R 83 、 -(CH 2 ) a SO 3 H、 -(CH 2 ) a SO 3 - 、 -(CH 2 ) a OSO 3 H、 -(CH 2 ) a SO 3 - 、 -(CH 2 ) a P.S. 3 H、 -(CH 2 ) a P.S. 3 - 、 -(CH 2 ) a PO 3 H 2 、 -(CH 2 ) a PO 3 H - 、 -(CH 2 ) a PO 3 = 、 -(CH 2 ) a OPO 3 H 2 、 - (CH 2 ) a O.P.O. 3 H - ,or, - (CH 2 ) a O.P.O. 3 2- and R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 58 , R 59 , R 60 , R 61 , R 62 , R 63 , R 64 , R 65 , R 66 , and R 67 Each of the following is independently -H or -CH 3 and R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , and R 27 each of which, independently of the other, -H, -CH 3 、 -(CH 2 ) f NR 28 C(O)NR 29 (CH 2 ) g (CH 2 CH 2 O) h R 38 、 -(CH 2 ) f NR 30 CSNR 31 (CH) 2 ) g (CH) 2 CH 2 O) h R 39 、 -(CH 2 ) f C(O)NR 32 (CH 2 ) g (CH 2 CH 2 O) h R 40 、 -(CH 2 ) f S(O) 2 NR 33 (CH 2 ) g (CH 2 CH 2 O) h R 41 、 -(CH 2 ) f NR 34 S(O) 2 (CH 2 ) g (CH 2 CH 2 O) h R 42 、 -(CH 2 ) f NR 35 C(O)(CH 2 ) g (CH 2 CH 2 O) h R 43 、 -(CH 2 ) f NR 36 C(O)O(CH 2 ) g (CH 2 CH 2 O) h R 44 、 -(CH 2 ) f OC(O)NR 37 (CH 2 ) g (CH 2 CH 2 O) h R 45 、 -CO(AA) or -CONH(PS); R 28 , R 29 , R 30 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , R 42 , R 43 , R 44 , and R 45 Each of the following is independently -H or -CH 3 and R 68 , R 69 , R 70 , R 71 , R 72 , R 73 , R 74 , R 75 , R 76 , R 77 , R 78 , R 79 , and R 80 each of which, independently of the other, -H, -CH 3 、 -(CH 2 ) p S(O) 2 NR 84 (CH 2 ) q (CH 2 CH 2 O) s R 81 、 -(CH 2 ) p NR 85 S(O) 2 (CH 2 ) q (CH 2 CH 2 O) s R 83 、 -(CH 2 ) p NR 86 C(O)(CH 2 ) q (CH 2 CH 2 O) s R 85 、 - (CH 2 ) p N.R. 86 C(O)O(CH 2 ) q (CH 2 CH 2 O) s R 87 ,or, - (CH 2 ) p O.C. (O) N.R. 88 (CH 2 ) q (CH 2 CH 2 O) s R 89 and R 81 , R 82 , R 83 , R 84 , R 85 , R 86 , R 87 , R 88 , and R 89 Each of the following is independently -H or -CH 3 and Each (AA) is, independently of each other, a polypeptide chain comprising one or more natural or non-natural α-amino acids linked together by peptide bonds; each (PS) is, independently of the other, a sulfated or non-sulfated polysaccharide chain comprising one or more monosaccharide units linked together by glycosidic bonds; t and u are, independently of each other, 1, 2, 3, 4, or 5; Each of a, d, g, l, and q, independently of each other, is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; Each of c, f, k, and p, independently of one another, is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; Each of b, j, e, h, o, and s is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100; Each NH2R moiety optionally includes a protecting group.
8. 8. The method of claim 7, wherein said NH2R is D-serine containing a benzyl protecting group.
9. 9. The method according to claim 7 or 8, Each NH2R moiety of compound 5 contains a protecting group PG, As shown in the formula below, The method further comprises cleaving the protecting group PG to produce compound 6: 【Chemistry 8】
10. 10. The method of claim 9, the NH2R is D-serine, The compound 6 is (2R,2'R)-2,2'-((3,6-diaminopyrazine-2,5-dicarbonyl)bis(azanediyl))bis(3-hydroxypropanoic acid) represented by the following structural formula. 【Chemistry 21】
11. A method for producing a substituted pteridine compound or a salt thereof, comprising the steps of: As shown in the formula below, A method comprising step 1a of anodizing compound 7 shown below in the presence of a base and a solvent to produce compound 8 shown below. In the above formula, R i and R ii are independent of each other, Hydrogen (in that case, R i and R ii is hydrogen), optionally substituted alkyl; optionally substituted esters; optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; optionally substituted aryl or optionally substituted heteroaryl; optionally substituted alkoxy; optionally substituted —C(O)-alkyl; optionally substituted amino; an optionally substituted polyol ether or an optionally substituted polyether; A polypeptide chain (AA); and Polysaccharide chains (PS).
12. 12. The method of claim 11, As shown in the formula below, The method further comprises step 1b of contacting said compound 8 or a salt thereof with a base in the presence of a solvent to produce pyrazine compound 9 or a salt thereof: 【Chemistry 23】
13. 13. The method of claim 12, The method further comprises the step of contacting said pyrazine compound 9, or a salt thereof, with a base in the presence of a solvent to produce pyrazine compound 10, or a salt thereof: 【Chemistry 24】
14. 14. The method of claim 13, The method further comprises reacting said pyrazine compound 10 or a salt thereof with compound 4, which is an acid salt of NH2R, in a solvent to produce compound 11 or a salt thereof. 【Chemistry 16】 In the above formula, Each NH2R is independently (i) a polypeptide chain comprising one or more natural or unnatural α-amino acids linked together by peptide bonds; or (ii) NH(R 1 ) and Each R 1 are independent of each other, -(CH 2 ) a (CH 2 CH 2 O) b (CH 2 ) c NR 10 P. 11 (CH 2 ) d (CH 2 CH 2 O) e R 20 、 -(CH 2 ) a (CH) 2 CH 2 O) b (CH) 2 ) c NR 12 CSNR 13 (CH) 2 ) d (CH) 2 CH 2 O) e R 21 、 -(CH 2 ) a (CH 2 CH 2 O) b (CH 2 ) c P. 14 (CH 2 ) d (CH 2 CH 2 O) e R 22 、 -(CH 2 ) a (CH 2 CH 2 O) b (CH 2 ) c NR 15 SO 2 (CH 2 ) d (CH 2 CH 2 O) e R 23 、 -(CH 2 ) a (CH 2 CH 2 O) b (CH 2 ) c SO 2 NR 16 (CH 2 ) d (CH 2 CH 2 O) e R 24 、 -(CH 2 ) a (CH 2 CH 2 O) b (CH 2 ) c NR 17 P. 2 ) d (CH 2 CH 2 O) e R 25 、 -(CH 2 ) a (CH 2 CH 2 O) b (CH 2 ) c NR 18 CO 2 (CH 2 ) d (CH 2 CH 2 O) e R 26 、 -(CH 2 ) a (CH 2 CH 2 O) b (CH 2 ) c P.S. 19 CO 2 (CH 2 ) d (CH 2 CH 2 O) e R 27 、 -(CH 2 ) c OR 68 、 -CH 2 (CHOH) c R 69 、 -CH 2 (CHOH) c CO 2 H、 -(EHCC) 2 H) c CO 2 H、 -(CH 2 ) c NR 70 R 71 、 -CH[(CH 2 ) f NH 2 ] c CO 2 H、 -CH[(CH 2 ) f NH 2 ] c CH 2 OH、 -CH 2 (1) 2 ) c CH 2 NR 72 R 73 、 -(CH 2 CH 2 O) e R 74 、 -(CH 2 ) t CO(CH 2 CH 2 O) e R 75 、 -(CH 2 ) u (CH 2 CH 2 O) j (CH 2 ) k NR 58 C(O)NR 59 (CH 2 ) l (CH 2 CH 2 O) o R 76 、 -(CH 2 ) u (CH 2 CH 2 O) j (CH 2 ) k NR 60 C(S)NR 61 (CH 2 ) l (CH 2 CH 2 O) o R 77 、 -(CH 2 ) u (CH 2 CH 2 O) j (CH 2 ) k C(O)NR 62 (CH 2 ) l (CH 2 CH 2 O) o R 78 、 -(CH 2 ) u (CH 2 CH 2 O) j (CH 2 ) k S(O) 2 NR 63 (CH 2 ) l (CH 2 CH 2 O) o R 79 、 -(CH 2 ) u (CH 2 CH 2 O) j (CH 2 ) k NR 64 S(O) 2 (CH 2 ) l (CH 2 CH 2 O) o R 80 、 -(CH 2 ) u (CH 2 CH 2 O) j (CH 2 ) k NR 65 C(O)(CH 2 ) l (CH 2 CH 2 O) o R 81 、 -(CH 2 ) u (CH 2 CH 2 O) j (CH 2 ) k NR 66 C(O)O(CH 2 ) l (CH 2 CH 2 O) o R 82 、 -(CH 2 ) u (CH 2 CH 2 O) j (CH 2 ) k OC(O)NR 67 (CH 2 ) l (CH 2 CH 2 O) o R 83 、 -(CH 2 ) a SO 3 H、 -(CH 2 ) a SO 3 - 、 -(CH 2 ) a OSO 3 H、 -(CH 2 ) a SO 3 - 、 -(CH 2 ) a P.S. 3 H、 -(CH 2 ) a P.S. 3 - 、 -(CH 2 ) a PO 3 H 2 、 -(CH 2 ) a PO 3 H - 、 -(CH 2 ) a PO 3 = 、 -(CH 2 ) a OPO 3 H 2 、 - (CH 2 ) a O.P.O. 3 H - ,or, - (CH 2 ) a O.P.O. 3 2- and R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 58 , R 59 , R 60 , R 61 , R 62 , R 63 , R 64 , R 65 , R 66 , and R 67 Each of the following is independently -H or -CH 3 and R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , and R 27 each of which, independently of the other, -H, -CH 3 、 -(CH 2 ) f NR 28 C(O)NR 29 (CH 2 ) g (CH 2 CH 2 O) h R 38 、 -(CH 2 ) f NR 30 CSNR 31 (CH) 2 ) g (CH) 2 CH 2 O) h R 39 、 -(CH 2 ) f C(O)NR 32 (CH 2 ) g (CH 2 CH 2 O) h R 40 、 -(CH 2 ) f S(O) 2 NR 33 (CH 2 ) g (CH 2 CH 2 O) h R 41 、 -(CH 2 ) f NR 34 S(O) 2 (CH 2 ) g (CH 2 CH 2 O) h R 42 、 -(CH 2 ) f NR 35 C(O)(CH 2 ) g (CH 2 CH 2 O) h R 43 、 -(CH 2 ) f NR 36 C(O)O(CH 2 ) g (CH 2 CH 2 O) h R 44 、 -(CH 2 ) f OC(O)NR 37 (CH 2 ) g (CH 2 CH 2 O) h R 45 、 -CO(AA) or -CONH(PS); R 28 , R 29 , R 30 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , R 42 , R 43 , R 44 , and R 45 Each of the following is independently -H or -CH 3 and R 68 , R 69 , R 70 , R 71 , R 72 , R 73 , R 74 , R 75 , R 76 , R 77 , R 78 , R 79 , and R 80 each of which, independently of the other, -H, -CH 3 、 -(CH 2 ) p S(O) 2 NR 84 (CH 2 ) q (CH 2 CH 2 O) s R 81 、 -(CH 2 ) p NR 85 S(O) 2 (CH 2 ) q (CH 2 CH 2 O) s R 83 、 -(CH 2 ) p NR 86 C(O)(CH 2 ) q (CH 2 CH 2 O) s R 85 、 - (CH 2 ) p N.R. 86 C(O)O(CH 2 ) q (CH 2 CH 2 O) s R 87 ,or, - (CH 2 ) p O.C. (O) N.R. 88 (CH 2 ) q (CH 2 CH 2 O) s R 89 and R 81 , R 82 , R 83 , R 84 , R 85 , R 86 , R 87 , R 88 , and R 89 Each of the following is independently -H or -CH 3 and Each (AA) is, independently of each other, a polypeptide chain comprising one or more natural or non-natural α-amino acids linked together by peptide bonds; each (PS) is, independently of the other, a sulfated or non-sulfated polysaccharide chain comprising one or more monosaccharide units linked together by glycosidic bonds; t and u are, independently of each other, 1, 2, 3, 4, or 5; Each of a, d, g, l, and q, independently of each other, is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; Each of c, f, k, and p, independently of one another, is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; Each of b, j, e, h, o, and s is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100; Each NH2R moiety optionally includes a protecting group.
Citation Information
Patent Citations
pyrazine-2,5-diamines as new developer-type oxidation dye precursors
DE102016205615A1
Fluorescent Pyrazine Derivatives and Their Use in Renal Function Assessment
JP2008525487A
Compositions and methods for evaluating ocular vasculature
JP2018524272A
Modular handguard device for a firearm
US20180010881A1
3,6-diamino-2,5-pyrazinedicarbonitrile
US5294711A
